Sheller in Chronicle of Higher Education on Major Drug Fraud
The Chronicle of Higher Education 2013-11-08 Federal prosecutors on Thursday concluded another multibillion-dollar settlement with a major pharmaceutical company accused of illegally marketing its drugs. In this case, the company was Johnson & Johnson, the total payment was $2.2-billion, and the key drug was Risperdal, which was approved by federal regulators to treat schizophrenia in […]
Sheller in Philadelphia Inquirer on $2.2B Risperdal Settlement
Philadelphia Inquirer 2013-11-05 Sheller, P.C.’s representation of whistleblowers totals over $6 billion, with three of the top five pharmaceutical settlements in history: 2009: Pfizer $2.3 billion (Geodon) 2009: Eli Lilly & Co. $1.4 billion (Zyprexa) 2013: Johnson & Johnson $2.2 billion (Risperdal, Invega) and in 2010 : Astra Zeneca $520 million (Seroquel) WASHINGTON – Health-care […]
$2.2 Billion Settlement
With the $2.2B Risperdal settlement, Sheller, P.C.’s representation of whistleblowers totals over $6.4 billion, with three of the top five pharmaceutical settlements in history 2009: Pfizer $2.3 billion (Geodon) 2009: Eli Lilly & Co. $1.4 billion (Zyprexa) 2013: Johnson & Johnson $2.2 billion (Risperdal, Invega) 2010 : Astra Zeneca $520 million (Seroquel) WASHINGTON, November 4, […]
Sheller Spars With FDA
Lawyer Spars With FDA Over J&J Risperdal Court Documents by Ed Silverman, Pharmalot In an unusual tactic, an attorney is prodding the FDA to seek documents that purportedly detail side effects caused by the Risperdal antipsychotic, but cannot be released publicly due to a court order. The documents were sealed by a Philadelphia judge as […]
Sheller on Lawyer Spars With FDA Over J&J Risperdal Court Documents
Pharmalot.com, Pharmaceutical Industry News 2013-07-11 In an unusual tactic, an attorney is prodding the FDA to seek documents that purportedly detail side effects caused by the Risperdal antipsychotic, but cannot be released publicly due to a court order. The documents were sealed by a Philadelphia judge as part of ongoing litigation over claims the Johnson […]
Sheller in Philadelphia Inquirer “FDA Slow to Ask J&J for Drug Data”
The Philadelphia Inquirer & “Fierce Pharma” 2013-07-10 The U.S. Food and Drug Administration is dragging its feet in addressing concerns that Johnson & Johnson’s antipsychotic drugs Risperdal and Invega are dangerous, a Philadelphia lawyer says in letters to the federal agency, and the company should allow those alleging harm from the medicines to release information […]
Sheller Risperdal settlements front page Legal Intelligencer
2012-10-05 The first trial in which evidence was taken in the mass tort litigation over Risperdal, the antipsychotic drug that plaintiffs have claimed causes males to grow breasts, was settled as part of a group of five cases that resolved this week for undisclosed amounts, according to the plaintiffs’ lawyers and a statement from the […]
